BGNE - BeiGene - Stock Price & Dividends

Exchange: USA Stocks • Country: Cayman Islands • Currency: USD • Type: Common Stock • ISIN: US07725L1026

Cancer, Oncology, Medicines, Pharmaceuticals, Treatments

BeiGene Ltd is a biopharmaceutical company that focuses on developing and commercializing innovative cancer treatments worldwide. Their product portfolio includes a range of oncology medicines, such as BRUKINSA for blood cancers, TEVIMBRA for solid tumor and blood cancers, and PARTRUVIX for solid tumor malignancies.

Their pipeline also includes XGEVA, which treats bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone. Additionally, they offer BLINCYTO for acute lymphoblastic leukemia, KYPROLIS for relapsed or refractory multiple myeloma, and REVLIMID for multiple myeloma.

BeiGene's portfolio also includes VIDAZA for myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia, as well as SYLVANT for idiopathic multicentric Castleman disease. Furthermore, they have QARZIBA for neuroblastoma, POBEVCY for metastatic colorectal cancer, liver cancer, and non-small cell lung cancer, and BAITUOWEI for breast and prostate cancers.

The company is also developing various inhibitors, including Sonrotoclax, BGB-10188, and Ociperlimab, as well as antibodies like Zanidatamab and BGB-A445. They have collaborations with several companies, including Shoreline Biosciences, Amgen, Novartis, Bristol Myers Squibb, and Shandong Luye Pharmaceutical, among others.

Founded in 2010, BeiGene is headquartered in Grand Cayman, the Cayman Islands, and has a strong commitment to innovation and improving patient outcomes. With a robust pipeline and strategic collaborations, the company is poised to make a significant impact in the oncology landscape.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for BGNE - BeiGene  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for BGNE - BeiGene  - Stock Price & Dividends

BGNE Stock Overview

Market Cap in USD 15,627m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2016-02-03

BGNE Stock Ratings

Growth 5y -6.93
Fundamental -53.1
Dividend -
Rel. Performance vs Sector -2.23
Analysts 4.55/5
Fair Price Momentum 133.74 USD
Fair Price DCF -

BGNE Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

BGNE Growth Ratios

Growth 12m -22.49%
Growth Correlation 12m -62%
Growth Correlation 3m -2%
CAGR 5y 4.35%
CAGR/Mean DD 5y 0.13
Sharpe Ratio 12m -0.57
Alpha vs SP500 12m -46.73
Beta vs SP500 5y weekly 0.90
ValueRay RSI 68.73
Volatility GJR Garch 1y 44.67%
Price / SMA 50 -2.88%
Price / SMA 200 -7.75%
Current Volume 378k
Average Volume 20d 238.5k

External Links for BGNE Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of BGNE stocks?
As of July 14, 2024, the stock is trading at USD 152.17 with a total of 378,036 shares traded.
Over the past week, the price has changed by +3.49%, over one month by -9.48%, over three months by +7.69% and over the past year by -23.11%.
What are the forecast for BGNE stock price target?
According to ValueRays Forecast Model, BGNE BeiGene will be worth about 147.9 in July 2025. The stock is currently trading at 152.17. This means that the stock has a potential downside of -2.79%.
Issuer Forecast Upside
Wallstreet Target Price 268.2 76.2
Analysts Target Price 292.5 92.2
ValueRay Target Price 147.9 -2.79